 clinic virolog effect recombin human granulocyte-macrophag colony-stimul factor patient chemotherapi human immunodefici virus-associ non-hodgkin lymphoma result random trial thirti patient human immunodefici viru hiv non-hodgkin lymphoma nhl chemotherapi cyclophosphamid doxorubicin vincristin prednison chop subcutan recombin human granulocyte-macrophag colony-stimul factor rgm-csf addit therapi recombin rgm-csf dose micrograms/kg/d day earli rgm-csf first patient day rgm-csf chemotherapi cycl subsequ patient control group delay rgm-csf group mean nadir absolut neutrophil count /L mean durat neutropenia day chemotherapi cycl neutropenia fever day fever neutropenia reduct chemotherapi dosag frequent delay chemotherapi administr signific differ patient control group earli rgm-csf group median level serum antigen baselin valu control rgm-csf group week administr first cycl chemotherapi third week chemotherapi median antigen level baselin control group baselin valu rgm-csf group stimul hiv replic effect chang hiv activ clinic outcom treat patient clinic signific find unclear complet respons rate control rgm-csf earli rgm-csf group surviv time month